Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Bio-Rad Laboratories (BIO) one of those stocks right now? A quick glance at the ...

Bio-Rad is back on the table as an attractive value proposition once again. The firm is well-positioned to unlock tremendous value for shareholders looking ahead, in my estimation. Profitability is a ...

When a chemical fire caused widespread evacuations and sent a chlorine plume over a Black Atlanta suburb last year, it was not the first accident of its kind. That worries residents there. It's been a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Most of Kelderman's pay was in ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for ...

I rate Bio-Rad (BIO) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect. For 2025, the company expects a 0.25% growth rate for its revenues, which might ...

Bio-Rad Laboratories, Inc. BIO posted fourth-quarter 2024 adjusted earnings per share (EPS) of $2.90, which missed the Zacks Consensus Estimate of $2.93 by 1.0%. The bottom line decreased 6.4% from ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for ...